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HIGHLIGHTS  
1. I.p. administered L-kynurenine doesn’t alter systemic blood pressure in anaesthetized mice. 
2. I.p. administered L-kynurenine induces cerebral hypoperfusion transients in anaesthetized 
mice.  
3. Kynurenic acid should be accounted for the observed dysregulation of the pial circulation. 
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ABSTRACT  
The kynurenine pathway is a cascade of enzymatic steps generating biologically active 
compounds. L-kynurenine (L-KYN) is a central metabolite of tryptophan degradation. In the 
mammalian brain, L-KYN is partly converted to kynurenic acid (KYNA), which exerts 
multiple effects on neurotransmission. Recently, L-KYN or one of its derivatives were 
attributed a direct role in the regulation of the systemic circulation. L-KYN dilates arterial 
blood vessels during sepsis in rats, while it increases cerebral blood flow (CBF) in awake 
rabbits. Therefore, we hypothesized that acute elevation of systemic L-KYN concentration 
may exert potential effects on mean arterial blood pressure (MABP) and on resting CBF in the 
mouse brain. C57Bl/6 male mice were anesthetized with isoflurane, and MABP was 
monitored in the femoral artery, while CBF was assessed through the intact parietal bone with 
the aid of laser speckle contrast imaging. L-KYN sulphate (L-KYNs) (300 mg/kg, i.p.) or 
vehicle was administered intraperitoneally. Subsequently, MABP and CBF were continuously 
monitored for 2.5 hrs. In the control group, MABP and CBF were stable (69±4mmHg and 
100±5%, respectively) throughout the entire data acquisition period. In the L-KYNs-treated 
group, MABP was similar to that, of control group (73±6mmHg), while hypoperfusion 
transients of 22±6%, lasting 7±3min occurred in the cerebral cortex over the first 60-120 min 
following drug administration. In conclusion, the systemic high-dose of L-KYNs treatment 
destabilizes resting CBF by inducing a number of transient hypoperfusion events. This 
observation indicates the careful consideration of the dose of L-KYN administration by 
interpreting the effect of kynurenergic manipulation on brain function. By planning clinical 
trials basing on kynurenergic manipulation possible vascular side effects should also be 
considered. 
 
 
 
ABBREVATIONS 
L-KYN, L-Kynurenine; KYNA, Kynurenic acid; α7nACh, α7 nicotinic acetylcholine; 
GPR35, G-protein-coupled receptor 35; NMDA, N-methyl-D-aspartate; L-KYNs, L-
Kynurenine sulfate; CBF, cerebral blood flow; MABP, mean arterial blood pressure; rCBFx, 
cerebrovascular autoregulatory index; α-amino-3-hydroxy-5-methyl-4-isoxazole propionic 
acid (AMPA), eNOS, endothelial nitric oxide synthase; nitric oxide synthase (NOS); 
neuropeptide Y (NPY) 
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INTRODUCTION 
L-kynurenine (L-KYN) is a central metabolite of tryptophan degradation: known as  
kynurenine pathway, it is a cascade of enzymatic steps generating biologically active 
compounds (Vécsei et al., 2013). Growth in the level of systemic L-KYN is particularly 
associated with a dose-dependent increase of its direct downstream metabolite kynurenic acid 
(KYNA) in the central nervous system, and in the periphery (Swartz et al., 1990). Elevation of 
brain KYNA content is correlated with attenuation in the concentration of extracellular 
glutamate (Carpenedo et al., 2001), dopamine (Rassoulpour et al., 2005) and acetylcholine 
(Zmarowski et al., 2009) in distinct cortical and subcortical brain regions. KYNA influences 
neurotransmission through multiple pre-and postsynaptic pathways. KYNA directly attenuates 
neurotransmitter release, partly by inhibiting α7 nicotinic acetylcholine (α7nACh) receptor 
located on presynaptic terminals (Hilmas et al., 2001), and partly by stimulating G-protein-
coupled receptor 35 (GPR35) localized on neurons and astrocytes (Alkondon et al., 2015; 
Berlinguer-Palmini et al., 2013; Guo et al., 2008). However, the significance of KYNA action 
on α7nACh receptor was queried recently (Albuquerque and Schwarcz, 2013). Nonetheless, 
KYNA hinders glutamatergic postsynaptic currents by competitive antagonism of N-methyl-
D-aspartate (NMDA) receptor at its allosteric glycine binding site (Birch et al., 1988). 
Moreover, in the periphery and in the brain during neuroinflammation, KYNA promotes anti-
inflammatory responses due to activation of aryl hydrocarbon receptor and GPR35 expressed 
by immune-cells (Moroni et al., 2012; Nguyen et al., 2010), as well as it presumably also 
modulates neuron survival through extrasynaptic NMDA receptor (Parsons and Raymond, 
2014; Schwarcz, 2016). Besides its receptor-mediated actions, KYNA in itself is a potent 
antioxidant (Lugo-Huitrón et al., 2011).  
Therefore, elevation of brain KYNA level, either by administration of L-KYN or 
pharmacological manipulation of the availability of the kynurenine pathway enzymes, has 
become an attractive strategy to attenuate neuroinflammatory responses and to protect against 
glutamate induced excitotoxicity associated with ischemic brain injury (Tan et al., 2012; 
Vécsei et al., 2013). Accordingly, we and our collaborators achieved neuroprotection by the 
administration of L-KYN sulfate (L-KYNs) in experimental models of neurodegenerative 
diseases and ischemic stroke (Gigler et al., 2007; Németh et al., 2004; Vámos et al., 2009). In 
these studies, neuroprotection was achieved partly by the administration of 300 mg/bwkg L-
KYNs.  
Acute or chronic elevation of systemic L-KYN content  has already been suggested to 
trigger alteration in the behavior of rodents (Chess et al., 2007; Chess and Bucci, 2006; 
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Vécsei and Beal, 1990; Wonodi and Schwarcz, 2010). Moreover, pre- and postnatal chronic 
L-KYN exposure in rodents provoked long-lasting neurochemical and behavioral 
abnormalities manifested in adulthood (Liu et al., 2014; Pocivavsek et al., 2014). We have 
shown formerly, that in naïve mice an acute administration of 300 mg/bwkg L-KYNs 
provoked hyperlocomotion and spatial working memory deficits, in conjunction with 
attenuated c-Fos protein expression in the striatum and the hippocampus (Varga et al., 2015). 
Accordingly, we have chosen the same dosage to obtain comparable information about the 
potential vascular effects of L-KYNs. 
Recently, both L-KYN and KYNA were suggested to have some direct role in the 
regulation of the cardiorespiratory system. First, in the ventral part of the medulla and in the 
nucleus of the solitary tract many kynurenine aminotransferase-immunoreactive neurons were 
found in association with NMDA receptors involved in the control of blood pressure (Kapoor 
et al., 1997). Second, in a spontaneous hypertensive rat strain a missense mutation of 
kynurenine aminotransferase-I gene, a product of which converts L-KYN to KYNA, with 
abnormally low KYNA levels in the medulla were linked to the formation of systemic high 
blood pressure (Kapoor et al., 1994; Kwok et al., 2002).  Yet, L-KYN administration dose 
dependently attenuated the elevated blood pressure (Wang et al., 2010). Third, L-KYN was 
identified as an endothelium-derived vasodilator, contributing to peripheral arterial relaxation 
and regulation of blood pressure during systemic inflammation in rats (Wang et al., 2010). 
Furthermore, an intravenous administration of low-dose L-KYN (1mg/kg) has been shown to 
increase cerebral blood flow (CBF) in conscious rabbits, mediated by activation of cholinergic 
and nitric oxide pathways (Sas et al., 2003). Moreover, kynurenine aminotransferase-
immunopositive astrocytes and interneurons in the cerebral cortex and in distinct subcortical 
areas are in an ideal anatomical position to control local CBF (Guidetti et al., 2007; Herédi et 
al., 2016). Finally, region specific CBF reductions can be seen in schizophrenic patient 
suffering psychotomimetic distortions (Liddle et al., 1992; Mathew et al., 1982), whereas the 
cerebrospinal fluid content of L-KYN and KYNA are significantly elevated (Schwarcz et al., 
2001).  
Taken together, we hypothesized that acute elevation of systemic L-KYN concentration, 
which is primarily thought to be neuroprotective in ischemia, but also linked to the 
pathophysiology of various neuropsychiatric diseases and systemic inflammatory response, 
may exert potential effects on the systemic vasoregulation or CBF in adult healthy animals. 
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MATERIAL and METHODS 
Animals and housing conditions 
The experimental procedures were approved by the National Food Chain Safety and 
Animal Health Directorate of Csongrád County, Hungary. The procedures were performed 
according to the guidelines of the Scientific Committee of Animal Experimentation of the 
Hungarian Academy of Sciences (updated Law and Regulations on Animal Protection: 
40/2013. (II. 14.) Gov. of Hungary), following the EU Directive 2010/63/EU on the 
protection of animals used for scientific purposes, and reported in compliance with the 
ARRIVE guidelines. Efforts were made to minimize the number of animals used and to 
reduce pain and discomfort. Before the experimental procedures, all the mice were in normal 
health and had no neurological deficits. All of the experiments were approved by the 
following ethical license: XX/01593/I/2010. 
Surgical procedures 
12-14 weeks old adult male C57Bl/6J mice (n=16, body weight 28±3 g) were used. The 
animals were obtained from The National Institute of Oncology (Budapest, Hungary), were 
group-housed under normal 12-h light/dark cycle, with ad libitum access to food and tap 
water. On the day of experiments, the animals were anesthetized with isoflurane (1.5% 
induction, 1% maintenance in N2O:O2, 70:30%) and allowed to breath spontaneously through 
a head mask. In order to avoid the production of airway mucus, atropin (0.1%, 0.01 ml) was 
injected intramuscularly shortly before the surgical procedures. Body temperature was 
maintained at 37˚C using a thermostatic heating pad (TMP-5b, Supertech Kft., Pécs, 
Hungary). The left femoral artery was cannulated for the continuous acquisition of mean 
arterial blood pressure (MABP). Then, the mice were transferred to a stereotaxic frame 
(David Kopf Instruments, CA, USA) and fixed in a prone position. A midline incision was 
made above the sagittal suture and the scalp was gently pulled aside. Lidocain (1%) was 
administered topically before opening the skin. The periosteum was removed with blunted 
forceps, the skull surface was rinsed with saline, and then covered with a thin layer of UV 
light adhesive (UV683 Light Curing Adhesive, Permabond Ltd., Wessex, UK) to prevent 
drying throughout the measurement. CBF was assessed through the intact parietal bone with 
the aid of laser speckle contrast imaging (PeriCam PSI HR System
®
, Perimed, Järfälla, 
Sweden) as described in detail elsewhere (Ayata and Dunn, 2004). Briefly, the field of view 
centered on the bregma was illuminated in a diffuse manner by a laser diode at 785 nm 
wavelength, and raw speckle images were captured by a camera positioned 10 cm above the 
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animal’s head. The field of view was adjusted to cover an area of 10 x 13 mm at high 
magnification of 20 µm/pixel covering both hemispheres. Raw speckle images were obtained 
at a sampling rate of 0.33 Hz, and computed to color-coded contrast images (Figure 1A) by a 
dedicated software (PimSoft 1.5.4.8, Perimed, Järfälla, Sweden). In summary, laser speckle 
flowmetry is a quantitative tool to assess noninvasively two-dimensional hemodynamic 
changes in the pial circulation of mice. Data obtained by this method informs about a relative 
perfusion level of the observed cortical area with high temporal and spatial resolution, 
whereas elevation in the values denote cerebral hyperemia, and decrease denote cerebral 
hypoperfusion. 
Drug administration and experimental protocols 
Animals were randomly assigned to two different treatment protocols (n=8/group).  
After taking a baseline of 20 min, a bolus injection of L-KYNs (300 mg/bwkg) or vehicle (0.1 
M phosphate buffer) of the same volume (0.2 ml) was administered intraperitoneally.  
Subsequently, MABP and CBF were continuously monitored at least for 2.5 hours. All 
chemicals were purchased from Sigma, St. Louis, MO, USA. 
Data analysis  
All variables were simultaneously acquired and stored using a personal computer with 
dedicated softwares (PeriSoft 2.5.5 for BP and PimSoft 1.5.4.8 for CBF Perimed, Järfälla, 
Sweden). Data analysis was conducted by custom written scripts in a MATlab environment 
(MathWorks Inc.,MA, USA).  
To determine the changes in CBF, identical regions of interest were positioned over 
each hemisphere, over the somatosensory cortical area (Figure 1A and C). The size of this 
area was 2.5±0.3 mm
2
. Raw CBF changes were expressed relative to baseline by using the 
average CBF value of the first 5 min (100%) and the recorded biological zero obtained after 
terminating the experiment (0%) as reference points. CBF values were smoothed to the 
median of 5 points (15-second periods), and a moving average of 10 points (30-second 
periods) was calculated to decrease the inherent noise of the signal (Mahé et al., 2011). The 
integrity of cerebral autoregulation  was determined by calculating a cerebrovascular 
autoregulatory index (rCBFx) as described in detail elsewhere (Hinzman et al., 2014). First, 
MABP was downsampled to 0.33Hz. Second, Pearson correlation coefficients were calculated 
between 20 consecutive (300 seconds) time averaged data points (15-second periods) of 
MABP and CBF. Based on previous studies, rCBFx<0.3 was accepted to indicate intact 
cerebrovascular autoregulation (Zweifel et al., 2008). 
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In order to discriminate significant CBF variations reliably, a range of normal CBF 
variation was determined according to a threshold level (±1.5 stdev) for each individual 
measurement (Figure 1B and D). Because of spontaneous vasomotor activities and inherent 
noise of the signal, the CBF of the isoflurane-anesthetized mice is appreciably fluctuates. In 
order not to involve these to our analyses, we focused only to the slower components of the 
CBF variation. Consequently, when CBF dropped below the determined threshold range for 
more than 15 seconds (5 consecutive time points), a cerebral hypoperfusion transient, when 
exceeded that, a cerebral hyperemic transient was noted and the events were taken for further 
quantitative analysis. Time periods with rCBFx˃0.3 were excluded from the analysis in order 
to disregard passive CBF variations independent of drug effect. The following elements of the 
CBF transients were characterized: peak amplitude, duration, and magnitude expressed as 
area under the curve (AUC) (Fig.1D). 
Statistical analysis was performed using the software SPSS (IBM SPSS Statistics for 
Windows, Version 22) or the inbuilt statistical functions of MATLAB (MathWorks Inc., MA, 
USA). The distribution of the data was tested with the Shapiro-Wilk normality test. Outliers 
were filtered with Grubbs test. For repeated measures with within-subjects factor of time and 
between-subjects factor of treatment, a mixed analysis of variance (ANOVA) model was 
applied on time averaged 30-min epochs of the MABP. Variables derived from the CBF 
variations were evaluated with Welch two sample t-test with Bonferroni correction to control 
type one error rate. Correlation analysis relied on a one-tailed Pearson test. Data are given as 
mean±stdev and levels of significance were defined as p**<0.01, and p***<0.001.  
RESULTS 
Systemic blood pressure 
MABP was stable in both experimental groups throughout the entire data acquisition 
period. The mean MABP calculated for the total duration of data acquisition was 69.46±4.24 
mmHg in the control group and 72.99±5.63 mmHg in the L-KYNs group. Statistical analysis 
revealed no significant difference neither between the defined epochs nor between the 
treatments. 
Cerebral blood flow variation in the somatosensory cortex 
The relative CBF values derived from the left and right hemispheres revealed strong, 
positive correlation (r≥0.95***), therefore they were averaged and analyzed as a single value 
for each animal.  
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The frequency and the magnitude of hyperemic transients were negligible in both 
experimental groups.  In the control group, hypoperfusion transients occurred in some but not 
all of the animals, and their temporal distribution was quite random. Conversely, 
hypoperfusion transients evolved in all the L-KYNs-treated animals, typically emerged 60-
120 min following L-KYNs administration, and were markedly more pronounced (Fig. 2). As 
such, the peak amplitude of the hypoperfusion transients was greater in the treated group (-
22.16±5.9%) compared to the control (-12.74±2.6%), t(14.073)=5.175, p<0.001 (Fig. 2A). 
The CBF reduction lasted longer in the treated group (6.5±3.2 min) than in the control 
(2.1±1.2 min), t(11.545)=-4.201, p=0.003 (Fig. 2B). In addition, the magnitude of the CBF 
reduction characterized by the AUC was greater in the treated group (5348±2350% x s) than 
that in the control (1199±580% x s), t(9.692)=-5.48, p<0.001 (Fig. 2C). Cerebral 
autoregulation remained intact during the hypoperfusion transients, as reflected by the rCBFx 
values under 0.3 (Fig.1C and D).  
 
DISCUSSION 
Here we have shown that the L-KYNs treatment destabilized resting CBF of isoflurane-
anesthetized mice by inducing a number of transient hypoperfusion events, with no 
simultaneous influence on MABP. The present data are at variance with previous observations 
attributing a vasodilator and blood pressure lowering effect to L-KYN (Sas et al., 2003; Wang 
et al., 2010), which may be due to the various L-KYN concentrations used, or the induction or 
lack of anesthesia, or species difference. Isoflurane dose used in our study causes minimal 
cardiac depression (Janssen et al., 2004), but, along with nitrous oxide (DiSesa et al., 1987) it 
might mask the blood pressure attenuating effect of L-KYN. On the other hand, the blood 
pressure attenuating effect of L-KYN was observed during systemic inflammation or 
hypertension only (Kwok et al., 2002; Wang et al., 2010), and is very likely insignificant in 
naïve animals. It was previously demonstrated, that administration of L-KYN at low dose 
promoted hyperemic responses in awake rabbits (Sas et al., 2003). Conversely, the current 
data show that high-dose L-KYNs treatment induces transient CBF reductions in anesthetized 
mice. Kynurenine pathway metabolites are normally present in mammals. However, 
variations in inducibility, spatio-temporal expression pattern of the enzymes during KYN 
catabolism are not completely clarified. Leklem and co-workers found that, urinary excretion 
of metabolites  following oral loading of tryptophan, L-kynurenine or 3-hydroxy- DL-
kynurenine,was much greater in rats as compared to cats (Leklem et al., 1969). Age-
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dependent changes in the expression of kynurenine aminotransferase (KAT) isoformes in 
mice was also described (Yu et al., 2006). Furthermore, physiological concentration of 
KYNA reveals prominent differences among mammalian species (Moroni et al., 1988). In 
summary, kynurenergic manipulation may exert age and species-dependent effect. 
Dose-dependent responses to various kynurenergic manipulations can be diverse. As 
such, KYNA was shown to facilitate excitatory postsynaptic potentials at low concentration, 
but it exerts inhibitory effect at higher-concentration, through dual actions on α-amino-3-
hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors (Prescott et al., 2006; Rózsa 
et al., 2008). Therefore, it is reasonable to propose that the effect of L-KYNs on CBF is also 
dose dependent.  
In the brain two spatially distributed routs exist for L-KYN metabolism: the quinolinic 
acid and the KYNA branches (Amori et al., 2009). The main source of quinolinic acid is the 
activated microglia, thus in a healthy, intact brain, catabolic activity of the enzymes located in 
this branch are relatively low (Guillemin et al., 2001). Therefore a bolus injection of L-KYNs 
is expected to be converted to KYNA with irreversible transamination catalyzed by 
kynurenine aminotransferases, located in perivascular astrocytes (Swartz et al., 1990) and in 
GAD67-immunopositive interneurons (Herédi et al., 2016). While our experimental 
conditions are likely to promote KYNA formation from L-KYNs, a modest increment of other 
downstream metabolites of the kynurenine pathway cannot be excluded. Indeed, their 
involvement in vasomotor regulation to the best of our knowledge has not been revealed. 
Since L-KYNs was administered in a buffered solution, furthermore, the brain KYNA 
production falls into the picomolar or nanomolar range, we propose that the de novo produced 
KYNA does not exert any effect on brain extracellular pH level. 
Cerebral hypoperfusion transients occurred over the time when L-KYN is known to 
penetrate the brain tissue and de novo synthetized KYNA is released to the extracellular space 
(Swartz et al., 1990; Zmarowski et al., 2009). This brief time window (60-120 min) following 
L-KYNs administration is thought to be insufficient for the accumulation of other kynurenine 
pathway metabolites in the extracellular space. Consequently, the observed CBF 
dysregulation is likely to be related to an elevated concentration of brain extracellular KYNA.  
While the molecular mechanism leading from elevated level of KYNA to various 
actions on different cell surface receptors to fluctuation in the extracellular level of distinct 
neurotransmitters to behavioral alterations are extensively investigated and increasingly 
elucidated (Schwarcz, 2016; Schwarcz et al., 2012; Vécsei et al., 2013), the mechanisms 
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leading to vascular diameter changes remain to be clarified. Clearly, a number of possible 
processes could be operative in our model. 
Cerebral cortical arteries were shown to express functional Mg
2+
-insensitive NMDA 
receptors on their endothelial surface, whereas binding of KYNA was verified to inhibit 
glutamate induced vasodilation via an endothelial nitric oxide synthase (eNOS) dependent 
way (LeMaistre et al., 2012). However, the relevance of this pathway in vivo was not 
confirmed yet, and thought to be significant during enhanced glutamate release typical of 
ischemic brain injury or epilepsy. Nevertheless, inhibition of endothelial NMDA receptor 
owing to KYNA accumulation is very feasible (LeMaistre et al., 2012). Considerable amount 
of KYNA is present in the blood circulation due to peripheral metabolization of L-KYN. 
Thus, attenuation of eNOS-dependent vasodilation, which has a major role in the regulation of 
the resting CBF (Attwell et al., 2010), could be accounted for the observed dysregulation in 
the pial circulation.  
The synthesis and release of vasodilator prostaglandins from astrocytes is driven by the 
fluctuation of intracellular Ca
2+
 concentration (Attwell et al., 2010; Howarth, 2014). Cortical 
astrocytes too express non-neuronal NMDA receptor (Lalo et al., 2006) and GPR35, a Gi-
protein coupled receptor (Moroni et al., 2012). KYNA action on both receptor types leads to 
attenuated intracellular Ca
2+
 levels, associated with hindered release of vasoactive substance 
and impaired control of CBF. Furthermore, astrocytes contribute to the management of basal 
CBF by tonic regulation of blood supply via steady-state vasodilation of cortical arterioles. In 
acute rat brain slices of sensory-motor cortex, reduction in astrocyte Ca
2+
 concentration 
promoted vasoconstriction in adjacent arterioles, which can be mimicked in awake mice with 
the blockade of cyclooxygenase-1 enzyme (Rosenegger et al., 2015). Moreover, the inhibition 
of cyclooxygenase-1 enzyme, which is predominantly harbored in astrocytes, was shown to 
reduce resting CBF in mice (Niwa et al., 2001). Thus, this astrocytic pathway could be 
implicated in the cerebral hypoperfusion transients in response to high dose L-KYNs 
administration. 
Interestingly, topical application of KYNA did not affect resting cerebellar CBF in 
anesthetized rats (Li and Iadecola, 1994), nor did it affect the diameter of pial arterial vessels 
in anesthetized newborn piglet (Bari et al., 2006). Still, when NMDA-receptor dependent 
vasodilation was induced either by NMDA or electrical stimulation, KYNA dose-dependently 
attenuated evoked postsynaptic currents and vascular dilatory responses (Bari et al., 2006; Li 
and Iadecola, 1994). However, it should be noted, that discrepancies may evolve due to 
anatomical (cerebellar vs cerebral) or age differences (newborn vs adult). Correspondingly, 
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similar CBF reduction to what we observed was triggered in intact rat parietal cortex with 
MK-801, a non-competitive antagonist of NMDA receptor (Park et al., 1989). Accordingly, 
these findings may reinforce NMDA receptors as one of the target involved in KYNA-
dependent hypoperfusion. The conceivable mechanisms via NMDA responses can be 
interpreted were discussed partly (non-neuronal NMDA receptors). However, the possibility 
that the KYNA-induced hypoperfusion are secondary to a decreased neuronal-network 
activity, and glucose utilization cannot be excluded (Birch et al., 1988; Busija et al., 2007; 
Schwarcz, 2016; Schwarcz et al., 2012; Vécsei et al., 2013). In support of this view, 
intracerebroventricular administration of KYNA induced mild suppression of 
electrocorticographic activity in anesthetized rats (Yokoi et al., 1998), and a net neuronal 
hyperpolarization, was found to be associated with concurrent pial arteriolar vasoconstriction 
in rat somatosensory cortex (Devor et al., 2007). Could the cerebral hypoperfusion transients 
found here reflect a lowered neuronal net metabolism? To answer this question further 
experiment should be done focusing on the glucose utilization and the electrophysiological 
activity of the cerebral cortex. 
The observed KYNA-related cerebral hypoperfusion transients occurred almost 
simultaneously in both hemispheres in a similar manner, implying a global action of KYNA. 
On the other hand, we monitored CBF variations only in the exposed parietal cortical surface. 
Cholinergic inputs to the parietal cortex, ascend from subcortical neurons, located in the 
nucleus basalis of Meynert (Hamel, 2006; Sato et al., 2002). These afferents innervate cortical 
arteries, local nitric oxide synthase (NOS) and neuropeptide Y (NPY) immunoreactive 
interneurons and perivascular astrocytes. The tonic activation of cholinergic inputs promotes 
vasodilation in the cortex, mediated by nicotinic cholinergic receptors, while the selective 
inactivation of cholinergic neurons in the basal forebrain induce significant (24-40%) 
hypoperfusion, mainly in the posterior parietal and temporal cortical regions (Waite et al., 
1999). It is possible that KYNA can significantly hinder the impact of basal forebrain cortical 
- cholinergic inputs, by attenuating acetylcholine release from the cholinergic nerve terminals 
and blocking α7nACh receptors located on interneurons (Zmarowski et al., 2009). Taken 
together, the increased concentration of KYNA may cause cerebral hypoperfusion transients 
in the parietal cortex by inhibition of its cholinergic innervation. 
 
CONCLUSIONS 
In summary, our data demonstrate that systemic administration of high-dose L-KYNs induces 
cerebral hypoperfusion transients while it does not alter systemic blood pressure. The 
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impairment of the kynurenine pathway metabolism is increasingly considered to be involved 
in the occurrence and the progression of metabolic dysfunctions observed in various 
neurodegenerative diseases. Thus, manipulation of the availability of kynurenine metabolites 
as a potential therapeutic approach has been extensively investigated recently. Although, up to 
this point the possibility that this manipulation might interfere with the cerebrovascular 
regulation was not taken into account. In conclusion, the L-KYNs treatment destabilizes 
resting CBF by inducing a number of transient hypoperfusion events, a phenomenon, that 
should be considered by interpreting the effect of kynurenergic manipulation on brain 
function. 
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FIGURE CAPTIONS 
Fig. 1. Representative cerebral blood flow (CBF) images of the cortical surface were obtained 
with laser speckle contrast analysis, and subsequently pseudo-colored to visualize the 
intensity of perfusion in a vehicle-treated animal (A) and an L-KYNs-treated mouse (B). 
Regions of interest used for CBF assessment are outlined with black in the images. 
Representative traces in panels C and D show variation in CBF (red trace),  mean arterial 
blood pressure (MABP; green trace), and cerebrovascular autoregulatory indexes (rCBFx, 
blue trace) taken from a vehicle-treated (C) or an L-KYNs-treated (D) animal. A CBF 
threshold (±1.5 stdev of the mean; red horizontal dotted lines) was determined to evaluate 
CBF variations. CBF below this range was taken relevant for the quantitative analysis:  peak 
amplitude (vertical arrow), duration (horizontal arrow), and area under the curve (AUC; grey 
colored area). The traces depict CBF variation without concomitant changes in MABP 
following vehicle or L-KYNs administration (vertical dotted line). Cerebral autoregulation 
was intact (rCBFx<0.3; red horizontal line) at times when CBF decreased below threshold 
(indicated by arrowheads). Hashtags above the CBF traces mark the time points when the 
speckle images in panel A and B were taken. 
 
Fig. 2. Quantitative assessment of hypoperfusion transients after L-KYNs with respect to 
vehicle treatment: (A) Maximum amplitude of hypoperfusion transients; (B) Duration of 
hypoperfusion transients; (C) Magnitude of hypoperfusion transients, expressed as area under 
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the curve. Data are given as mean±stdev. Statistical analysis relied on Welch two sample t-
test with Bonferroni correction. Note the significant effect of the L-KYNs treatment on all of 
the observed parameters. Statistical significance was determined as p**<0.01, and 
p***<0.001. 
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